Silver Bullet Therapeutics Launches OrthoFuzIon Bone Screw System At DKOU German Congress Of Orthopedics And Traumatology
Recent CE Mark Clearance Includes Reduction of Infection Claim
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced that it is formally launching its antimicrobial OrthoFuzIon Bone Screw System at the DKOU German Congress of Orthopedics and Traumatology on October 26-29 in Berlin.
Recommended AI News: Orbis Systems Partners with Signzy to Expand Identity Verification Services to India
Silver Bullet Therapeutics’ OrthoFuzIon product line will be featured at the Argomedical booth at Nr. 61 in Hall 4.2.
The OrthoFuzIon Orthopedic Bone Screw System is a comprehensive antimicrobial bone screw product line for orthopedic procedures. The OrthoFuzIon Bone Screws are indicated for open reduction and internal fixation (ORIF) fracture surgeries and are plated to inhibit microbial colonization and reduce implant related infection in revision surgery due to implant infection or primary surgery in patients who are at-risk of implant infections.
Paul Chirico, President and CEO of Silver Bullet Therapeutics stated, “Silver Bullet is very excited to be launching our product line at the prestigious German Society of Orthopedics with Argomedical, our respected distribution partner. Patients who receive revision surgery due to an implant related infection or those that are at risk of implant infections from a primary surgery will benefit from the technology and significantly broad product offering. ”
“Orthopedic trauma surgeons treat challenging injuries in patients that may have complex medical comorbidities. I believe that The Silver Bullet Therapeutics antimicrobial OrthoFuzIon Bone Screw line, which delivers local peri-implant antimicrobial silver ions, will help us decrease surgical infection complications after surgical fixation” noted Amir Matityahu, MD, an internationally renowned orthopedic trauma surgeon, Professor of Orthopaedic Surgery at the University of California, San Francisco, and Chairman of Surgery, Chief of Orthopaedics, and Director of Orthopedic Trauma at Regional Medical Center of San Jose. He is also a Fellow of the American Academy of Orthopedic Surgery and International Corresponding Member of the German Society for Orthopaedics and Trauma (Deutsche Gesellschaft für Orthopädie und Unfallchirurgie e V.).
“Argomedical has a proud history of representing state-of-the-art products that directly benefit patients and surgeons”, said Phil Kropf, CEO of Argomedical. “The Silver Bullet Therapeutics’ antimicrobial OrthoFuzIon Bone Screw System is not only simple but a disruptive medical device that may change the practice of trauma orthopedics almost immediately.”
Recommended AI News: Productiv Revolutionizes the Digital Work Experience with SaaS Intelligence Platform
According to a 2015 article by Hackett et al published in the Journal of the American Academy of Orthopedic Surgery: “Musculoskeletal infections are a leading cause of patient morbidity and rising healthcare expenditures. The incidence of musculoskeletal infections, including soft-tissue infections, periprosthetic joint infection, and osteomyelitis, is increasing. Cases involving both drug-resistant bacterial strains and periprosthetic joint infection in total hip and total knee arthroplasty are particularly costly and represent a growing economic burden for the American healthcare system.” Silver Bullet Therapeutics has developed a coating for bone screws since they penetrate the cortical shell of a bone into the intramedullary space to not only alleviate the morbidity and the costs associated orthopedic infection complications, but minimize the disincentive on caring for high-risk patients.
Silver Bullet Therapeutics has built an extensive intellectual property portfolio that has allowed the company to develop and validate coating processes for a wide variety of metallic, polymer and electronic medical devices.
Recommended AI News: Iron Mountain Wins Google Cloud Financial Services Customer Award
[To share your insights with us, please write to firstname.lastname@example.org]